ADiMaB Raises $6 Million

ADiMaB, an antibody startup launched by GlycoFi founder Tillman Gerngross, has raised $6 million in Series A funding, according to VentureWire. Backers include Polaris Venture Partners and SV Life Sciences, which both backed GlycoFi, which was sold last year to Merck. Gerngross also served as a venture partner with SV Life Sciences.